IV TXA

Phase 3Small molecule

MMassachusetts General Hospital

IV TXA is one of 7 small molecule programs targeting Tranexamic Acid. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Tranexamic AcidRecruiting

Tranexamic AcidPhase 3

Recruiting

Competition

Competitive Landscape

6 competitors in Tranexamic Acid

#DrugCompanyPhaseTrials

Cyklokapron

JJ Molner

Approved

156 2

Pitressin

AAultman Health Foundation

Approved

3 3

IV TXA

MMassachusetts General Hospital

Phase 3

1 4

Tranexamic Acid Pill

HHenry Ford Health System

Phase 3

1 5

Adrenaline

AARS Pharmaceuticals, Inc.

Preclinical

2 6

IV Atropine

AAssiut University

Preclinical

1 7

Progynova

UUniversitair Ziekenhuis Brussel

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Post-ApprovalRecruiting

Tranexamic Acid

NCT07131592

Clinical

Trials by Indication[1]

Anesthesia1 trial

EEG Studies of IV Methylphenidate-Induced Emergence From Anesthesia

Withdrawn·MMassachusetts General Hospital·Phase 1/2·NCT02429076

Sedation1 trial

EEG Study of IV Methylphenidate-Induced Emergence From Propofol Sedation

Withdrawn·MMassachusetts General Hospital·Phase 1/2·NCT03610282

Tranexamic Acid1 trial

Effect of Intravenous and Topical Tranexamic Acid on Drain Output in Breast Reduction Surgery

Recruiting·MMassachusetts General Hospital·Phase 4·NCT07131592·160 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for IV TXA. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IV TXA compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IV TXA. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Massachusetts General Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: MMassachusetts General Hospital

IV TXA

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Anesthesia1 trial

Sedation1 trial

Tranexamic Acid1 trial

References

Drug Info

Quick Facts

Related News